Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

10.64 +0.82 (+8.35%)
Official Closing Price Updated: 8:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc

< Previous 1 2
...
32 33 34 35 36 37 38 39 Next >
Psychedelic Stock Gainers And Losers From January 20, 2022
GAINERS: Small Pharma (OTC: 
Via Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC: 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Strengthening ‘Emerging Best-in-Class Position’ in Evolving Industry
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Psychedelic Stock Gainers And Losers From January 18, 2022
GAINERS: Cybin (AMEX: 
Via Benzinga
Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS
New Awakn Study Shows Ketamine Has Potential To Treat Alcoholism Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: 
Via Benzinga
Cybin Notes 'Milestone' Step with USPTO Notice of Allowance for CYB004
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advi... 
Via Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) Notes ‘Milestone’ Step with USPTO Notice of Allowance for CYB004
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes ‘Milestone’ Step with USPTO Notice of Allowance CYB004
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana
On Tuesday, three public companies in the psychedelics/biotech space announced significant milestones in their drug development pipelines. 
Via Benzinga
Cybin CEO Participation in Upcoming Events Recognizes Company Expertise
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advi... 
Via Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Participation in Upcoming Events Recognizes Company Expertise
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures IRB Approval for Feasibility Study Using Kernel’s Quantitative Neuroimaging Technology
Via Investor Brand Network
Why Cybin Shares Are Rising
Cybin Inc (NASDAQ: CYBN) shares are trading higher after the company announced an Institutional Review Board granted approval for a Cybin-sponsored feasibility study using Kernel... 
Via Benzinga
Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain
From Cybin Inc.
Via Business Wire
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Participation in Upcoming Events Recognizes Company Expertise
Via Investor Brand Network
Cybin Highlights Adelia's Milestone Achievement
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Cybin (NYSE: CYBN), a biotechnology... 
Via Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) Highlights Adelia’s Milestone Achievement
Via Investor Brand Network
Pure-Play Marijuana- & Psychedelic Compounds-Based Drug Stocks Index Is Down By 66% From 2021 High
There are 16 remaining constituents of our Marijuana & Psychedelic Compounds-Based Drug Stocks Index is now DOWN -65.9% from its highs in 2021. Here are the details for each of its constituents. 
Via Talk Markets
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes that Adelia Has Reached Milestone Achievement
Via Investor Brand Network
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Key Meeting with UK Regulatory Agency
Via Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Milestone Notice of Allowance for Revolutionary Treatment of Anxiety Disorders
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Support Low-Cost/No-Cost Psychedelic Clinic for Underserved Communities
Via Investor Brand Network
Cybin (NEO: CYBN) (NYSE American: CYBN) Receives Milestone Notice of Allowance
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Witnessing Advancement in R&D Pipeline
Cybin (NYSE: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently released its financial and operating... 
Via Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Witnessing Advancement in R&D Pipeline
Via Investor Brand Network
Exposures Product Safety
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Witnessing Swift Advancement in R&D Pipeline, Overall Business
Via Investor Brand Network
Exposures Product Safety
Steep Decline In Cannabis & Psychedelic Compounds-Based Drug Stocks Continues: DOWN -16.6% MTD
All 12 constituents in the Marijuana & Psychedelic Compounds-Based Drug Stocks Index continue to decline. How do their performances compare month-to-date and YTD? 
Via Talk Markets
Cybin (NYSE American: CYBN) (NEO: CYBN) Issues 2021 Year-End Summary
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Issues 2021 Year-End Summary
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2
...
32 33 34 35 36 37 38 39 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.